Supriya Lifescience Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Supriya Lifescience Ltd is ₹ 693.3 as of 05 May 15:30 . The P/E Ratio of Supriya Lifescience Ltd changed from 26.1 on March 2022 to 31.4 on March 2025 . This represents a CAGR of 4.73% over 4 yearsThe P/E Ratio of Vaishali Pharma Ltd changed from 32.9 on March 2021 to 209.7 on March 2025 . This represents a CAGR of 44.84% over 5 years The Market Cap of Supriya Lifescience Ltd changed from ₹ 3967 crore on March 2022 to ₹ 5903 crore on March 2025 . This represents a CAGR of 10.45% over 4 yearsThe Market Cap of Vaishali Pharma Ltd changed from ₹ 171.9 crore on March 2021 to ₹ 134.85 crore on March 2025 . This represents a CAGR of -4.74% over 5 years The Revenue of Supriya Lifescience Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of Supriya Lifescience Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of Supriya Lifescience Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of Supriya Lifescience Ltd changed from 3.2 % on March 2021 to 4.28 % on March 2025 . This represents a CAGR of 5.99% over 5 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Supriya Lifescience Ltd

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Supriya Lifescience Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Supriya Lifescience Ltd or Vaishali Pharma Ltd?

Market cap of Supriya Lifescience Ltd is 5,571 Cr while Market cap of Vaishali Pharma Ltd is 96 Cr

What are the key factors driving the stock performance of Supriya Lifescience Ltd and Vaishali Pharma Ltd?

The stock performance of Supriya Lifescience Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Supriya Lifescience Ltd and Vaishali Pharma Ltd?

As of May 5, 2026, the Supriya Lifescience Ltd stock price is INR ₹692.2. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.43.

How do dividend payouts of Supriya Lifescience Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Supriya Lifescience Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.